中信证券股份有限公司 关于思创医惠科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券""保荐机构"）作为思创医 惠科技股份有限公司（以下简称"思创医惠""公司"）向不特定对象发行可转 换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所创业板股票上市规则》等有关规定，对思创医惠 2024 年度募集资金存放与 使用情况进行了审慎核查，并出具核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 1、非公开发行股票募集资金 经中国证券监督管理委员会证监许可〔2019〕1442 号文核准，并经贵所同 意，公司由主承销商财通证券股份有限公司采用非公开发行方式，向特定对象非 公开发行人民币普通股（A 股）股票 5,139.01 万股，发行价为每股人民币 11.15 元，共计募集资金 57,299.99 万元，坐扣承销和保荐费用 641.79 万元后的募集资 金为 56,658.20 万元，已由主承销商财通证券股份有限公司于 2019 年 11 月 12 日 汇入公司验资户。另减除上网发行费、招股说明书印刷费、申报会计师费 ...

目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告 ……………第 3—16 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕9333 号 第 1 页 共 16 页 四、工作概述 我们按照中国注册会计师执业准则的规定执行了鉴证业务。中国注册会计师 执业准则要求我们计划和实施鉴证工作，以对鉴证对象信息是否不存在重大错报 获取合理保证。在鉴证过程中，我们实施了包括核查会计记录等我们认为必要的 程序。我们相信，我们的鉴证工作为发表意见提供了合理的基础。 思创医惠科技股份有限公司全体股东： 我们鉴证了后附的思创医惠科技股份有限公司（以下简称思创医惠公司）管 理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供思创医惠公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为思创医惠公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 思创医惠公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 （叶肖剑） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年 12 月 6 日任职后，严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。本人 根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促进公司规范 运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事及相 应专门委员会的作用。 现将本人 2024 年度任职期间（2024 年 12 月 6 日至 2024 年 12 月 31 日）履 行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人叶肖剑，汉族，1975 年出生，中国国籍，无境外永久居留权，本科学历。 正高级会计师、美国注册管理会计师、国际注册内审师；浙江省特支 ...

2024 年度独立董事述职报告 （褚国弟） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年 12 月 6 日任职后，严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。本人 根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促进公司规范 运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事及相 应专门委员会的作用。 现将本人 2024 年度任职期间（2024 年 12 月 6 日至 2024 年 12 月 31 日）履 行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人褚国弟，汉族，1978 年出生，中国国籍，无境外永久居留权，本科学历， 毕业于浙江政法管理干部学院、浙江大学（自学考试）法学专业。曾荣获嘉兴市 十佳法律服务工 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在任何影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关法律法规、 规章制度中关于独立董事独立性的要求。本人对 2024 年独立性情况进行了自查， 并将自查情况提交公司董事会。 二、独立董事年度履职情况 （一）出席会议的情况 （梁立-已离任） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 （赵合宇-已离任） 本人作为思创医惠科技股份有限公司（以下简称"公司"或"思创医惠"） 的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办 法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》《公司章程》《独立董事工作制度》 等相关法律、法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利， 积极出席相关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立 审查。本人根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促 进公司规范运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独 立董事及相应专门委员会的作用。 现将本人 2024 年度任职期间（2024 年 1 月 1 日至 2024 年 12 月 5 日）履行 独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人赵合宇，男，汉族，1966 年出生，中国国籍，无境外永久居留权，会计 学硕士研究生学历，注册会计师，注册税务师。1991 ...

思创医惠科技股份有限公司 2024 年度独立董事述职报告 （刘银） 本人作为思创医惠科技股份有限公司（以下简称"公司"）的独立董事，在 2024 年度任职期间，本人严格按照《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》《公司章程》《独立董事工作制度》等相关法律、 法规及规范性文件的规定和要求，勤勉尽责、独立谨慎地行使权利，积极出席相 关会议，认真审议董事会各项议案，对公司重点关注事项进行了独立审查。本人 根据公司实际情况，充分发挥自身专业优势，提出了意见和建议，促进公司规范 运作，切实维护了公司和股东尤其是中小股东的利益，充分发挥了独立董事及相 应专门委员会的作用。 现将本人 2024 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人刘银，男，汉族，1969 年出生，中国国籍，无境外永久居留权，法学硕 士研究生学历。曾获中国贸易救济研究奖。2003 年 8 月至 2006 年 8 月，任环中 律师事务所律师；2006 年 8 月至 2007 年 7 月， ...

思创医惠科技股份有限公司 董事会关于独立董事独立性自查情况的专项报告 思创医惠科技股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《独立董事工作制度》等相关法律、法规和规章制度的规定 和要求，就公司在任独立董事叶肖剑先生、褚国弟先生、刘银先生的独立性情况 进行评估并出具如下专项意见： 经核查，公司独立董事叶肖剑先生、褚国弟先生、刘银先生已向公司出具《独 立董事独立性自查报告》，上述人员未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关 系或其他可能妨碍其进行独立客观判断的关系，不存在任何影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规章制度中关于 独立董事独立性的要求。 思创医惠科技股份有限公司董事会 2025 年 4 月 30 日 ...

Financial Performance - The company reported a significant operating loss due to a decline in overall revenue, primarily impacted by market competition, business model adjustments, and a decrease in order volume [4]. - The company's operating revenue for 2024 was ¥690,765,562.41, a decrease of 31.33% compared to ¥1,005,929,309.42 in 2023 [24]. - The net profit attributable to shareholders for 2024 was -¥501,509,765.24, showing an improvement of 42.64% from -¥874,349,214.78 in 2023 [24]. - The net cash flow from operating activities was -¥35,682,984.51, a decline of 402.72% compared to ¥11,787,364.46 in 2023 [24]. - The total assets at the end of 2024 were ¥2,189,795,268.31, down 15.53% from ¥2,592,337,624.35 at the end of 2023 [24]. - The company reported a basic earnings per share of -¥0.53 for 2024, improving by 50.00% from -¥1.06 in 2023 [24]. - The company's revenue from core business activities, after deducting other income, was ¥635,589,837.98 in 2024, down from ¥792,024,301.02 in 2023 [24]. - The company reported a significant reduction in investment cash outflow by 48.50% to ¥612,186,484.88 from ¥1,188,616,583.06 [89]. - The company reported a total revenue of 16,946.37 million CNY, with a net profit loss of 33,558.94 million CNY for its subsidiary, Yihui Technology [117]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the fiscal year 2024, representing a growth of 20% year-over-year [196]. Strategic Initiatives - The company plans to not distribute cash dividends, issue bonus shares, or increase capital using reserves [7]. - The company launched the "思创物联（苍南）" production base, marking a strategic transformation and upgrade in its IoT application business [32]. - The company is transitioning from a manufacturer to a digital service provider, addressing industry challenges with comprehensive solutions [35]. - The company is actively developing a group hospital business collaboration and data sharing cloud platform in line with national healthcare reform initiatives, aiming to improve resource utilization and healthcare service quality [40]. - The company is investing in the development of personal digital health records, utilizing IoT, AI, and cloud computing technologies to enable dynamic aggregation and sharing of personal health data [41]. - The company is focusing on expanding its market presence and developing new technologies to enhance its product offerings [165]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY earmarked for potential mergers and acquisitions [196]. - The company plans to increase its marketing budget by 30% to support the launch of new products and enhance brand visibility [197]. Market and Product Development - The company focuses on providing integrated solutions in sectors such as smart retail, supply chain management, and smart cities, leveraging RFID technology [32]. - The company is actively developing a smart retail management system and a smart supply chain platform to achieve full digitalization from inventory management to logistics [123]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024 [199]. - New product launches are expected to contribute an additional 300 million RMB in revenue in 2024, focusing on advanced medical technologies [199]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving healthcare solutions over the next two years [199]. Governance and Management - The company has established a fair and effective performance evaluation and incentive mechanism for senior management, combining basic salary with annual performance assessments [148]. - The company has maintained independence from its largest shareholder, with no interference in decision-making or operational activities reported during the period [154]. - The company has implemented a robust internal control system to manage risks and ensure the normal operation of business activities [151]. - The company has established a comprehensive internal audit system, with an independent internal audit department reporting directly to the audit committee [151]. - The company has seen a turnover in key management positions, which may impact its operational strategy moving forward [168]. - The company appointed Wu Qiong as the new General Manager on May 28, 2024, following the resignation of Hua Songyuan due to work adjustments [167]. Challenges and Risks - The company continues to face challenges in its smart healthcare segment, with slow project delivery and payment collection contributing to operational losses [4]. - The company faces intensified competition in the IoT and smart healthcare sectors, requiring improved core competitiveness and cost structure optimization [128]. - The company is facing litigation risks from investors, with 18 lawsuits currently filed against it [136]. - The company is monitoring international trade policies and exchange rate fluctuations to manage potential risks in its business operations [133]. Research and Development - The company has received 14 invention patents, 14 utility model patents, and 23 software copyrights during the reporting period, showcasing its commitment to innovation [62]. - The company is investing heavily in R&D, with a budget allocation of 200 million CNY for new technologies and product development [196]. - Research and development expenditures have increased by 20%, reflecting the company's commitment to innovation [165]. - The company has initiated a cost-reduction strategy projected to save 100 million RMB annually, enhancing overall profitability [199]. International Operations - The company exports its products to over 70 countries and regions, establishing long-term stable partnerships with more than 300 clients and agents globally [50]. - International sales accounted for 52.02% of total revenue, down 24.20% from the previous year [72]. - The company is planning to expand its overseas market presence through localized solutions for smart loss prevention and digital retail technologies [123]. Financial Management - The company has engaged in foreign exchange hedging to mitigate risks associated with currency fluctuations, aiming to reduce the impact on operational performance [102]. - The company has implemented risk control measures for foreign exchange hedging, including monitoring and aligning hedging contracts with expected cash flows [103]. - The company has not engaged in speculative derivative investments during the reporting period [104]. - The company has established a unified data management platform for IoT data collection and analysis, achieving a 60% completion rate in user data processing [87].

Financial Performance - The company's revenue for Q1 2025 reached ¥409,267,469.05, representing a 105.78% increase compared to ¥198,888,851.70 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥19,559,000.77, an improvement of 71.14% from a loss of ¥67,764,977.31 in the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥29,473,021.51, which is a 56.91% improvement from a loss of ¥68,404,999.56 year-over-year[5] - The weighted average return on equity improved to -3.45% from -7.81% year-over-year, reflecting better financial performance[5] - The net profit for the current period was -19,436,112.60, compared to -68,576,893.20 in the previous period, indicating an improvement[28] - Total comprehensive income for the current period was -24,150,857.83, compared to -68,984,875.95 in the previous period[29] - Basic and diluted earnings per share were both -0.02, an improvement from -0.07 in the previous period[29] Assets and Liabilities - The company's total assets decreased by 31.19% to ¥1,506,875,539.19 from ¥2,189,795,268.31 at the end of the previous year[5] - Total liabilities decreased to ¥941,673,340.52 from ¥1,600,932,000.91, a reduction of about 41.2%[25] - Cash and cash equivalents increased to ¥439,934,835.34 from ¥415,200,644.88, reflecting a growth of approximately 5.5%[23] - Accounts receivable decreased to ¥353,033,883.16 from ¥395,319,679.02, a reduction of about 10.7%[24] - The company reported a cash and cash equivalents balance of 364,501,022.89 at the end of the period, down from 482,439,364.81 in the previous period[32] Cash Flow - The cash flow from operating activities was ¥25,805,801.61, showing a slight increase of 1.13% compared to ¥25,518,697.95 in the same period last year[5] - Operating cash flow net amount was 25,805,801.61, slightly up from 25,518,697.95 in the previous period[32] - Cash inflow from operating activities totaled 256,886,487.62, an increase from 227,704,641.50 in the previous period[31] - Cash outflow from operating activities was 231,080,686.01, compared to 202,185,943.55 in the previous period[32] - Investment activities generated a net cash flow of 725,351,084.89, significantly higher than 169,699,667.33 in the previous period[32] Shareholder Information - The total number of common shareholders at the end of the reporting period is 73,798[10] - The largest shareholder, Cangnan Siga IoT Smart Partnership, holds 5.72% of shares, totaling 63,890,185 shares[10] - The first major shareholder changed from Yunhai Chain Holdings to Mr. Lu Nan and his concerted actor, Hangzhou Botai Investment Management[17] - The total number of shares held by the top 10 shareholders does not include shares lent through margin trading[11] - The top 10 shareholders include both domestic and foreign entities, with significant stakes held by natural persons and corporations[10] Investment and Expenses - Research and development expenses decreased by 45.88% to ¥17,324,427.07 from ¥32,012,601.95 in the same period last year, attributed to organizational adjustments[8] - The company plans to invest up to RMB 50 million in Zhejiang Mashang Technology Co., with a subscription price of RMB 3.50 per share[18] Asset Disposal and Gains - The company recorded a substantial increase in asset disposal gains of 13,057.24%, amounting to ¥7,794,790.23 compared to a loss of ¥60,157.81 in the previous year[8] - The company sold assets for a total of RMB 562 million, with payments received of RMB 40 million and RMB 372 million as the first installment[15] - The second installment of RMB 115 million has been received as part of the asset sale[16] Legal and Guarantees - The company received a guarantee deposit of ¥58 million from the former chairman to cover potential liabilities related to a lawsuit[21] - The company expects no financial loss from the alleged guarantee issue, as the former chairman has committed to cover any excess liabilities[21] Strategic Initiatives - The company is actively pursuing new strategies for market expansion and product development, although specific details were not disclosed in the call[20]